Clinical trial IJB-SYNERGY-012017
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer. Synergy Trial (IJB-SYNERGY-012017)
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Oui |
Sponsor | Institut Jules Bordet |
EudraCT Identifier | 2017-004651-23 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03616886 |
Inclusion criteria | Metastatic. ER-/PR-/HER2- |
Last update |